Titel: German Federal Institute for Risk Assessment (BfR)

Beginn: 12.11.2018, 10:15 -11:45 Uhr

Veranstaltungsort:
Kaiserin Friedrich-Haus
Robert-Koch-Platz 7
10115 Berlin

Referenten: Prof. Craig Jordan MD (Anderson Cancer Center, University of Texas, USA)

Weitere Informationen:
https://www.bfr-akademie.de/media/wysiwyg/Bf3R_Programmflyer.pdf

Kurzbeschreibung: Tamoxifen is the first SERM. Millions of women continue to benefit from long-term adjuvant tamoxifen treatment for breast cancer. Ideally, a SERM will be antiestrogenic to prevent cancers in the breast and uterus. Additionally, a SERM will be estrogenic to build bone, and reduce circulating cholesterol, to protect post-menopausal women from atherosclerosis and coronary heart disease. Osteoporosis and coronary heart disease are the two major death causes of elderly women. With our aging population, SERMs have become increasingly important as medicines in public health. New SERMs were needed to refine safety issues with tamoxifen. There are five SERMs approved by the food and drug administration. Raloxifene, basedoxifene, toremifene, and ospemifene all have discovery or chemical research links back to Jordan’s Tamoxifen Team laboratory. Mechanisms of action will be considered and issues of the development of anticancer drug resistance addressed.

Kontakt: German Federal Institute for Risk Assessment (BfR)
Max-Dohrn-Straße 8 – 10
10589 Berlin
Germany
Tel.: +49 (0)3018 412 3456
Fax: +49 (0)3018 412 63456
academy@bfr.bund.de
http://www.bfr.bund.de/

Veranstalter: German Federal Institute for Risk Assessment (BfR)

Schlagworte: Tierethik